Livial (tibolone) / Organon - LARVOL DELTA

The Effect of Tibolone on Body Weight, Body Fat, and Metabolic Components (ECO 2025) - No abstract available

Late-breaking abstract

Differential cardiovascular risks of menopausal hormone therapy: insights from a Korean cohort. (PubMed, Eur J Endocrinol) - No abstract available

Journal • Cardiovascular

Association between duration, initiation time, routes, and formulations of menopausal hormone therapy use and Alzheimer disease in women: A systematic review and meta-analysis. (PubMed, J Pharmacol Exp Ther) - "Tibolone increased AD risk (cohort, RR = 1.04, 95% CI: 1.01-1.07; case-control, OR = 1.07, 95% CI: 1.01-1.14)...MHT lowered AD risk in apolipoprotein E genotype 4 allele carriers, individuals with depression, and Americans. MHT regimens should be highly personalized."

Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Depression • Psychiatry • APOE

Study on the efficacy of different MHT protocols in intervening with cognitive function in perimenopausal and postmenopausal women with sleep disorder based on fNIRS detection (ChiCTR) - P=N/A | N=90 | Not yet recruiting | Sponsor: Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Sixth People's Hospital Affiliated to Shangh

New trial • CNS Disorders • Sleep Disorder

Relation between pelvic organ prolapse and menopausal hormone therapy: nationwide cohort study. (PubMed, Obstet Gynecol Sci) - "After menopause, tibolone and CEPM were associated with a reduced POP risk compared with non-MHT. Other oral MHT and transdermal estrogen were not associated with the risk of POP."

Journal

Update of the impact of menopausal hormone therapy on breast cancer risk. (PubMed, Eur J Cancer) - "Despite possible changes towards safer MHT prescribing, our data collected largely in early millennium show at least as large BC risk elevations in MHT users as seen in older studies."

Journal • Breast Cancer • Oncology • Solid Tumor

Response by Yuk et al to Letter Regarding Article, "Association of menopausal hormone therapy with risk of cardiovascular disease in Korean women". (PubMed, Eur J Endocrinol) - No abstract available

Journal • Cardiovascular

The effects of menopausal hormone therapy for the risk of systemic lupus erythematosus: A nationwide cohort study in Korea. (PubMed, Semin Arthritis Rheum) - "The utilization of MHT did not demonstrate a substantial impact on the development of SLE in postmenopausal women. Caution is required in the early stages of tibolone use."

Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Association of menopausal hormone therapy with risk of cardiovascular disease in Korean women. (PubMed, Eur J Endocrinol) - "There was an increased risk of CVD in MHT users. By regimen, tibolone use was associated with increased risk of CVD, whereas estrogen either alone or in combination with progestogen was not. There was no difference according to the type of estrogen. The type of progestogen seems to modify the results, since dydrogesterone was associated with reduced CVD risk."

Journal • Cardiovascular

PHARMACOLOGICAL OPTIONS FOR MANAGING BURNING MOUTH SYNDROME. (WRMC 2025) - "Other medications evaluated included: amisulpride, aripiprazole, bupivacaine, cannabis, duloxetine, gabapentin, lysozyme-lactoperoxidase, melatonin, milnacipran, naltrexone, olanzapine, palmitoylethanlamide, paroxetine, pramipexole, pregabalin, sertraline, tibolone, and vortioxetine...Conclusions Although few studies have evaluated the use of pharmacological agents in the management of BMS, several have demonstrated efficacy including ALA, clonazepam, and capsaicin. Providers may refer to this review when managing patients with BMS. Drug Mechanism of Actions and Adverse Effects"

Dyspepsia • Pain

Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. (PubMed, BMJ) - "Use of oral oestrogen-progestin therapy was associated with an increased risk of heart disease and venous thromboembolism, whereas the use of tibolone was associated with an increased risk of ischaemic heart disease, cerebral infarction, and myocardial infarction but not venous thromboembolism. These findings highlight the diverse effects of different hormone combinations and administration methods on the risk of cardiovascular disease."

Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Heart Failure • Myocardial Infarction • Venous Thromboembolism

Utilization and Expenditure on Medicines for the Prevention and Treatment of Osteoporosis: A Changing Landscape (ISPOR-EU 2024) - "Data was included on claims from 1st January 2011 to 31 December 2023 for dispensed medicines that are licensed for the management of osteoporosis; bisphosphonates (alendronate, ibandronate, risedronate), teriparatide, denosumab, selective oestrogen receptor modulators (SERMS) (raloxifene, bazedoxifene) and tibolone. This study highlights the changing landscape of osteoporosis prevention and treatment in Ireland, over a 13-year period. Further research into treatment adherence with these therapies is warranted, given an aging population and attendant increase in fractures with associated healthcare resource use."

Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Tibolone treatment after traumatic brain injury exerts a sex-specific and Y chromosome-dependent regulation of methylation and demethylation enzymes and estrogen receptors in the cerebral cortex. (PubMed, Biochim Biophys Acta Mol Basis Dis) - No abstract available

Journal • CNS Disorders • Vascular Neurology • ER

Menopause and endometriosis. (PubMed, Maturitas) - "Current recommendations lean towards prioritizing combined menopausal hormone therapy formulations or tibolone over estrogen-only therapies due to their potentially higher malignancy risk. The possible increased risk of osteoporosis and cardiovascular disease in postmenopausal women with endometriosis is likely linked to a history of surgical menopause at an earlier age, but more research is warranted. This narrative review summarizes the available literature and provides insights into the intricate connection between endometriosis and menopause, shedding light on pathogenesis, symptoms, oncologic risk, diagnosis, and treatment."

Journal • Review • Cardiovascular • Endometriosis • Gynecology • Oncology • Osteoporosis • Pain • Rheumatology • Women's Health

Effect of Chronic Tibolone Administration on Memory and Choline Acetyltransferase and Tryptophan Hydroxylase Content in Aging Mice. (PubMed, Brain Sci) - "In the case of TPH, no changes were observed with either TIB dose. These results show that long-term TIB administration improves memory without affecting locomotor activity and modulates cholinergic but not serotonergic systems in the hippocampus of aged male mice."

Journal • Preclinical • Breast Cancer • CNS Disorders • Oncology • Solid Tumor • CHAT

Menopausal Hormone Therapy and Osteoarthritis Risk: Retrospective Population-Based Study in South Korea. (PubMed, J Menopausal Med) - "MHT was associated with an increased risk of osteoarthritis, consistently observed across tibolone, EPT, and ET, particularly affecting joints other than the hip, with a trend toward an elevated risk of hip osteoarthritis."

Journal • Retrospective data • Immunology • Osteoarthritis • Pain • Rheumatology

Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder. (PubMed, Am J Psychiatry) - "Similar effectiveness was found for estrogen alone or combined with fixed or sequential progestogens (aHRs between 0.79 and 0.86), transdermal and oral formulations (aHRs 0.75-0.87), and for most specific formulations (aHRs 0.75-0.85), except tibolone (aHR=1.04, 95% CI=0.75-1.44) and formulations with dydrogesterone (aHR=1.05, 95% CI=0.85-1.30). The findings underscore the potential value of MHT in preventing psychosis relapse among women with SSD of menopausal age. These findings translate clinical evidence on the neuroprotective effects of estrogens to real-world settings, encompassing a group of women for whom current antipsychotic treatment options may be insufficient."

Journal • Real-world • Real-world effectiveness • Real-world evidence • CNS Disorders • Psychiatry • Schizophrenia

Comment on "Effect of tibolone versus hormone replacement therapy on lower urinary tract symptoms and sexual function". (PubMed, J Formos Med Assoc) - No abstract available

Journal

Response to letter to the editor "Effect of tibolone versus hormone replacement therapy on lower urinary tract symptoms and sexual function". (PubMed, J Formos Med Assoc) - No abstract available

Journal

Effects of tibolone combined with zoledronic acid on bone density, bone metabolism, and pain in postmenopausal patients with osteoporosis. (PubMed, Am J Transl Res) - "Tibolone combined with zoledronic acid significantly increases bone mineral density, improves bone metabolism, and reduces pain in PMO patients, with a safety profile comparable to that of monotherapy. This regimen should be considered for clinical use in treating PMO."

Journal • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis • Pain • Rheumatology

Effect Of Tibolone On Cortical and Trabecular Bone In Postmenopausal Women Compared With Estrogen Therapy (ASBMR 2024) - No abstract available

Clinical • Osteoporosis • Rheumatology

Effectiveness of Combination of Tibolone and Lactobacilli Plus Lactoferrin in Postmenopausal Women with Vulvar Vestibular Pain: A Preliminary Report. (PubMed, Nutrients) - "This study provides evidence that the combination of TIB+ Respecta® was effective in reducing symptoms related to vestibular pain and hypersensitivity in a postmenopausal setting."

Journal • Immunology • Infectious Disease • Pain • Vaginitis • Women's Health

Hormone replacement therapy and myocardial infarction and stroke in postmenopausal Korean women. (PubMed, Climacteric) - "Stroke risk was lower with tibolone use for ≥5 years or with EPT or ET use for 1-3 years or ≥5 years than non-users. Our study may support the beneficial effect of HRT by showing that Korean postmenopausal women who used HRT at a relatively younger and healthier age had a relative benefit for MI and stroke."

Journal • Cardiovascular • Coronary Artery Disease • Heart Failure • Myocardial Infarction

Directive clinique no 451 : Épaississement asymptomatique de l'endomètre chez les femmes ménopausées. (PubMed, J Obstet Gynaecol Can) - "DONNéES PROBANTES: Des recherches ont été faites dans les bases de données Medline, Cochrane et PubMed pour répertorier les articles pertinents évalués par des pairs et publiés en anglais dans la période de 1995 à 2022 qui traitent notamment des sujets suivants : épaississement asymptomatique de l'endomètre, cancer de l'endomètre, saignements postménopausiques, échographie endovaginale, biopsie de l'endomètre, sténose cervicale, hormonothérapies et endomètre, tamoxifène, tibolone et inhibiteurs de l'aromatase...RéSUMé DES MéDIAS SOCIAUX: Les femmes ménopausées présentent souvent un épaississement de la muqueuse utérine à l'échographie. En l'absence de saignements, un endomètre de moins de 11 mm d'épaisseur est rarement un problème grave, mais doit être évalué par un..."

Clinical guideline • Journal • Oncology

Guideline No. 451: Asymptomatic Endometrial Thickening in Postmenopausal Women. (PubMed, J Obstet Gynaecol Can) - "English language articles from Medline, Cochrane, and PubMed databases for relevant peer-reviewed articles dating from 1995 to 2022 (e.g., asymptomatic endometrial thickness, endometrial cancer, postmenopausal bleeding, transvaginal ultrasound, endometrial biopsy, cervical stenosis, hormone therapies and the endometrium, tamoxifen, tibolone, aromatase inhibitors). Postmenopausal women often have a thickening of the lining of the uterus found during ultrasound. Without bleeding, an endometrium <11 mm is rarely a serious problem but should be evaluated by a health care provider."

Clinical • Clinical guideline • Journal • Endometrial Cancer • Gynecology • Mood Disorders • Obstetrics • Oncology • Pain • Psychiatry • Solid Tumor